Indian drug makers looking to expand in Chinese pharma industry
According to a new report, pharma companies in India are increasingly entering the Chinese pharma industry through joint ventures.
List view / Grid view
According to a new report, pharma companies in India are increasingly entering the Chinese pharma industry through joint ventures.
The Middle Eastern country has a limited supply of vital medication needed for conditions such as cancer due to US trade blocks.
FDA approves Nubeqa (darolutamide) as a new treatment for men with non-metastatic castration-resistant prostate cancer.
The global pharmaceutical robots market is set to be worth $344.4m at the end of a forecast period, after seeing substantial growth.
A new study undertaken to better understand the economic impact of brand-brand competition finds this does not lower drug prices.
In another bid to lower medication prices in the US, Donald Trump has announced a draft plan to import drugs from Canada.
Project TWENTY21, a nationwide study to investigate medicinal cannabis, has launched in the UK in order to collect data on the therapeutics.
The commercial brand for Eurofins Alphora and Eurofins Amatsigroup is now Eurofins CDMO (Contract Development Manufacturing Organization).
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
EMA’s human medicines committee had cleared the cannabidiol oral solution, Epidiolex, for use to treat seizures.
Teva Pharmaceuticals, Endo Pharmaceuticals and Teikoku will pay almost $70 million to the US state for delaying drugs to keep prices high.
For the 7th time, PharmaLab, picks up the latest developments in regulations, quality control and assurance and in laboratory methods and systems.
Scientists have developed microrobots that can deliver medication to specific spots inside the body while being controlled from outside the patient.
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
The CMA alleges that a pharmaceutical company agreed to buy equal quantities of a pill from two drug suppliers, breaking competition law.